Table 2 Outcome of individual SNOT-22 items.

From: Impact of dupilumab on SNOT-22 domain and individual item scores in chronic rhinosinusitis with nasal polyps

SNOT-22 item

Baseline

6-month follow-up

p-value

Effect size r

Need to blow nose

3 (2.5-4)

1 (1–2)

< 0.001

0.83

Sneezing

3 (2–3)

1 (0–2)

< 0.001

0.67

Runny nose

3 (2–4)

1 (0–2)

< 0.001

0.74

Cough

2 (0–3)

0 (0-1.5)

< 0.001

0.50

Post nasal drip

3 (2–4)

1 (0–3)

< 0.001

0.78

Thick nasal discharge

3 (2–4)

1 (0–2)

< 0.001

0.80

Ear fullness

2 (1-3.5)

0 (0–1)

< 0.001

0.65

Dizziness

1 (0–2)

0 (0–1)

< 0.001

0.40

Ear pain

0 (0–2)

0 (0–0)

< 0.001

0.39

Facial pain/pressure

0 (0–2)

0 (0–0)

< 0.001

0.51

Difficulty falling asleep

2 (1–3)

1 (0–2)

< 0.001

0.56

Wake up at night

3 (1–4)

1 (0–2)

< 0.001

0.59

Lack of a good night’s sleep

3 (2–4)

1 (0–3)

< 0.001

0.63

Wake up tired

3 (2–4)

1 (0–2)

< 0.001

0.68

Fatigue during the day

3 (1.5-4)

1 (0–2)

< 0.001

0.78

Reduced productivity

2 (1–3)

1 (0–2)

< 0.001

0.69

Reduced concentration

2 (1–3)

0 (0–2)

< 0.001

0.71

Frustrated/restless/ irritable

3 (1–4)

0 (0–2)

< 0.001

0.68

Sad

1 (0–3)

0 (0–1)

< 0.001

0.57

Embarrassed

2 (0–3)

0 (0–1)

< 0.001

0.68

Sense of taste/smell

5 (4–5)

1 (0–3)

< 0.001

0.82

Blockage/congestion of nose

4 (3–5)

2 (1–3)

< 0.001

0.89

  1. SNOT-22: Sinunasal Outcome Test 22. Variables are presented as median with interquartile range (IQR) in brackets.